Elahere received full FDA approval in ovarian cancer this year, but AstraZeneca believes its candidate may have activity at lower levels of FRα expression than AbbVie’s drug. The poster ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has failed to improve overall survival (OS) in non-small cell lung cancer (NSCLC), extending the list of molecules ...

AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on ...

Barclays analyst Emily Field maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The company’s shares closed yesterday at p12,000.00.

BARCELONA, Spain — An AstraZeneca immunotherapy, given both before and after surgery, improved survival rates in patients with bladder cancer, results that could reshape how muscle-invasive ...

As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could raise additional doubts around the first-in-class AKT inhibitor.

LONDON (Reuters) - Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival ...

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.

Sept 16 (Reuters) - Sanofi (SASY.PA), opens new tab and partner AstraZeneca (AZN.L), opens new tab have received approval from the U.S. Food and Drug Administration for a manufacturing line for ...

LONDON (Reuters) - Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival ...

Welcome, ladies and gentlemen, to AstraZeneca's Investor Conference Call ... and then tested in the full biomarker evaluable population. As I've already said, there's a greater prevalence for ...